Modeling platinum sensitive and resistant high-grade serous ovarian cancer: development and applications of experiment alsystems

被引:12
|
作者
Cunnea, Paula [1 ]
Stronach, Euan A. [1 ]
机构
[1] Imperial Coll London, Inst Reprod & Dev Biol, Ovarian Canc Act Res Ctr, Mol Therapeut Lab,Dept Canc & Surg, 4th Floor Labs,Du Cane Rd, London W12 ONN, England
来源
FRONTIERS IN ONCOLOGY | 2014年 / 4卷
关键词
high-grade serous ovarian cancer; platinum sensitive; resistant; tumor heterogeneity;
D O I
10.3389/fonc.2014.00081
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
High-grade serous ovarian cancer remains the most common sub-type of ovarian cancer and, characterized by high degrees of genomic instability and heterogeneity, is typified by a transition from early response to acquired resistance to platinum-based chemotherapy. Conventional models for the study of ovarian cancer have been largely limited to a set of relatively poorly characterized immortalized cell lines and recent studies have called into question the validity of some of these as reliable models. Here, we review new approaches and models systems that take into account advances in our understanding of ovarian cancer biology and advances in the technology available for their generation and study. We discuss primary cell models, 2D, 3D, and organotypic models, and "paired" sample approaches that capture the evolution of chemotherapy failure within single cases. We also overview new methods for non-invasive collection of representative tumor material from blood samples. Adoption of such methods and models will improve the quality and clinical relevance of ovarian cancer research.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Genetic variation in platinum-sensitive and platinum-resistant high-grade serous epithelial ovarian cancer
    Castellano, Tara
    Clark, Leslie H.
    Rashid, Naim
    Bae-Jump, Victoria
    CANCER RESEARCH, 2017, 77
  • [2] PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
    Morgan, Robert D.
    Clamp, Andrew R.
    Evans, D. Gareth R.
    Edmondson, Richard J.
    Jayson, Gordon C.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (04) : 647 - 658
  • [3] PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
    Robert D. Morgan
    Andrew R. Clamp
    D. Gareth R. Evans
    Richard J. Edmondson
    Gordon C. Jayson
    Cancer Chemotherapy and Pharmacology, 2018, 81 : 647 - 658
  • [4] Differentially expressed genes in platinum-resistant high-grade serous ovarian cancer
    Corey, Logan
    Alvero, Ayesha
    Tiwari, Nivedita
    You, Yuan
    Rattan, Ramandeep
    Kim, Seongho
    Mor, Gil
    Gogoi, Radhika
    GYNECOLOGIC ONCOLOGY, 2021, 162 : S130 - S131
  • [5] Evolution of platinum resistance in high-grade serous ovarian cancer
    Cooke, Susanna L.
    Brenton, James D.
    LANCET ONCOLOGY, 2011, 12 (12): : 1169 - 1174
  • [6] Metabolism of Estrogens: Turnover Differs between Platinum-Sensitive and -Resistant High-Grade Serous Ovarian Cancer Cells
    Poschner, Stefan
    Wackerlig, Judith
    Castillo-Tong, Dan Cacsire
    Wolf, Andrea
    von der Decken, Isabel
    Rizner, Tea Lanisnik
    Pavlic, Renata
    Meshcheryakova, Anastasia
    Fritzer-Szekeres, Monika
    Mechtcheriakova, Diana
    Thalhammer, Theresia
    Jaeger, Walter
    CANCERS, 2020, 12 (02)
  • [7] Consensus on the management of platinum-sensitive high-grade serous epithelial ovarian cancer in Lebanon
    Abdallah, Reem
    Atallah, David
    Bitar, Nizar
    Chahine, Georges
    Ghanem, Hady
    Ghosn, Marwan
    Kattan, Joseph
    Nasr, Fadi
    Makdessi, Joseph
    Shamseddine, Ali
    GYNECOLOGIC ONCOLOGY REPORTS, 2023, 47
  • [9] TARGETING AKT AND DNA-PK AS A THERAPEUTIC STRATEGY IN PLATINUM RESISTANT HIGH-GRADE SEROUS OVARIAN CANCER
    Rinne, N.
    Fotopoulou, C.
    Cunnea, P.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A231 - A232
  • [10] TARGETING AKT AND DNA-PK AS A THERAPEUTIC STRATEGY IN PLATINUM RESISTANT HIGH-GRADE SEROUS OVARIAN CANCER
    Rinne, N.
    Curry, E.
    Fotopoulou, C.
    Gabra, H.
    Cunnea, P.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A512 - A513